Fall Clinical 2025: Complete Conference Recap

To stay informed with the latest conference insights, follow us on social media and subscribe to receive our eNewsletters.

Previewing the 2025 Fall Clinical Dermatology Conference

The 25th annual meeting begins today and runs through October 26.

Fall Clinical 2025 Focuses on Practical Dermatology Education

Biologics, JAK inhibitors, and evolving treatment paradigms headline the Fall Clinical 2025 agenda.

Fall Clinical Brings ‘The Good Stuff’ to Dermatology, Says Lio

Lio describes Fall Clinical as an energizing, high-level dermatology meeting focused on practical takeaways and collaboration.

Familiar Faces Presenting at Fall Clinical 2025

Click through this slideshow to see what faces familiar to Dermatology Times will be on the speaker stand at Fall Clinical this week.

Early Systemic Therapy Crucial for Managing Prurigo Nodularis in Skin of Color

PN is increasingly recognized as a common and severe inflammatory skin disease disproportionately affecting patients with darker skin tones.

Top Advancements From 2025 on AD, HS, PsO, CSU, and More

James Del Rosso, DO; April Armstrong, MD, MPH; Mark Nestor, MD, PhD; Mark Lebwohl, MD; Linda Stein Gold, MD; and Darrell Rigel, MD, MS, presented some of the biggest updates in dermatology to close out the year.

Song Highlights Evolving Role of IL-23 Inhibitors in Psoriasis Care

A new IPC-endorsed framework simplifies psoriasis severity into “topical” versus “systemic” categories to guide treatment more effectively.

Envudeucitinib Demonstrates Sustained Efficacy and Safety in Moderate to Severe Plaque Psoriasis

Data from Fall Clinical 2025 detailed the results from the phase 2 STRIDE and ongoing open-label extension studies demonstrating the efficacy and safety of envudeucitinib, a selective TYK2 inhibitor.

Brad Glick, DO, MPH, FOACD, Highlights New Standards in AD Management

The AHEAD guidelines promote a new treatment standard for atopic dermatitis, emphasizing near-complete skin clearance and itch relief.

Icotrokinra Shows Durable Efficacy for PsO, Including Hard-to-Treat Areas, in 1-Year ICONIC-TOTAL Trial

New data from Johnson & Johnson's ICONIC-TOTAL study reveals icotrokinra's promising long-term efficacy and safety for treating challenging plaque psoriasis.

James Del Rosso, DO, Celebrates a Quarter Century of Dermatology Innovation in Las Vegas

Del Rosso recounts the meeting’s evolution and its consistent mission to bridge science and practice.

How GEP Testing Refines Risk Stratification in Melanoma and High-Risk cSCC

At Fall Clinical, Nguyen outlined how gene expression profile testing complements traditional staging systems—helping clinicians better identify melanoma and cSCC patients at the highest risk for recurrence.

Baricitinib Achieves Significant Hair Regrowth in Pediatric AA

At 52 weeks, the data presented at Fall Clinical showed that 64.8% and 63.3% of adolescents on baricitinib 4 mg achieved significant eyebrow and eyelash regrowth, respectively.
Integrating GLP-1 Therapy, Advancing CSU Care, and Expanding Access

At Fall Clinical 2025, Marc Serota, MD, discussed how GLP-1 therapies, new CSU treatments, and hybrid care models are reshaping dermatologic practice heading into 2026.

Clinical Trials Offer a ‘Win-Win’ for Patients and Progress

Lio believes that collaboration between science and industry is vital for translating research into meaningful patient benefits.

Aaron Farberg, MD, Explains Gene Profiling in Atopic Dermatitis

Gene expression profiling may allow clinicians, according to Farberg, to predict patient responses to targeted treatments.

“From Injectable to Ingestible:” TYK2 Inhibitors for PsO and the Ongoing Challenge of PPP

At Fall Clinical 2025, Ron Vender, MD, discussed the evolving psoriasis treatment landscape and the persistent challenge of managing palmoplantar pustulosis.

Second Generation TYK2 Inhibitors Transform Psoriasis Management

Benjamin Lockshin, MD, noted long half-life biologics may allow patients to maintain remission with minimal injections.

Socioeconomic Status Shapes Access to Advanced Psoriasis Therapies

New data presented at Fall Clinical 2025 reveal that patients in socioeconomically disadvantaged areas are significantly less likely to initiate biologic or small molecule treatments.

Navigating Biologics and JAK Inhibitors with James Del Rosso, DO

Emerging skin treatments present unique clinical challenges that must be anticipated by clinicians.

From 30 Tips to 3 Key Insights from 3 Experts

Discover essential dermatology insights from experts at the Fall Clinical Conference 2025, featuring innovative treatment tips and patient care strategies.

Exploring the OX40 Ligand Pathway and Chronic Itch

At Fall Clinical 2025, Shawn Kwatra, MD, presented insights on managing various cases of chronic itch, as well as understanding the OX40 ligand pathway as the “prequel to inflammation.”

Christopher Bunick, MD, PhD, Highlights JAK Inhibitors in AD Care

Clinicians are now aiming for treatment targets such as NRS 0–1, IGA 0–1, and EASI 90 to define successful AD management.

Integrating GLP-1 Therapy, Advancing CSU Care, and Expanding Access

At Fall Clinical 2025, Marc Serota, MD, discussed how GLP-1 therapies, new CSU treatments, and hybrid care models are reshaping dermatologic practice heading into 2026.

Clinical Trials Offer a ‘Win-Win’ for Patients and Progress

Lio believes that collaboration between science and industry is vital for translating research into meaningful patient benefits.

Aaron Farberg, MD, Explains Gene Profiling in Atopic Dermatitis

Gene expression profiling may allow clinicians, according to Farberg, to predict patient responses to targeted treatments.

“From Injectable to Ingestible:” TYK2 Inhibitors for PsO and the Ongoing Challenge of PPP

At Fall Clinical 2025, Ron Vender, MD, discussed the evolving psoriasis treatment landscape and the persistent challenge of managing palmoplantar pustulosis.

Second Generation TYK2 Inhibitors Transform Psoriasis Management

Benjamin Lockshin, MD, noted long half-life biologics may allow patients to maintain remission with minimal injections.

Our editors are on site and ready to gather your insights, both as a presenter or as an attendee! Reach out to us at DTEditor@mmhgroup.com for the opportunity to speak with one of our editors. Stay tuned to Dermatology Times all weekend for exclusive conference coverage and expert insights.